Comerford E, Norcross L, Sasane M, Zheng Y, Gnanasakthy A. Patient-reported outcome (PRO) data in oncology NDAs approved by the FDA (2018–2021): a review of criticism and concerns in comments from regulators. Poster presented at the National Comprehensive Cancer Network (NCCN) 2024 Annual Conference; April 5, 2024. Orlando, FL. [abstract] J Natl Compr Canc Netw. 2024 Apr 5; 22(2.5). doi: 10.6004/jnccn.2023.7146
Barnett C, Davenport MS, Montgomery JS, Kunju LP, Denton B, Piert M. 18F-choline PET/mpMRI for detection of significant prostate cancer, part 2: cost-effectiveness analysis. J Nucl Med. 2019 Dec;60(12):1705-12. doi: 10.2967/jnumed.119.225771
Davenport MS, Montgomery JS, Kunju LP, Siddiqui J, Shanka PR, Rajendiran T, Shao X, Lee E, Barnett CL, Denton BT, Piert M. 18F-choline PET/mpMRI for detection of clinically significant prostate cancer: Part 1. Improved risk stratification for MRI-guided transrectal prostate biopsies. J Nucl Med. 2019 Aug 16. doi: 10.2967/jnumed.119.225789.